BCG Unresponsive NMIBC Carcinoma In-Situ Videos

Underlying Mechanism of Action of N-803 + BCG Inducing Durable Complete Response in BCG Unresponsive NMIBC -Patrick Soon-Shiong

Patrick Soon-Shiong joins Ashish Kamat in a discussion on the mechanism of action of N-803 (Anktiva TM ) + BCG Inducing Durable Complete Response in BCG Unresponsive NMIBC. N-803 is a novel IL-15 superagonist complex consisting of an IL-15 mutant (IL-15N72D) bound to an IL-15 receptor α/IgG1 Fc fusion protein. Dr. Soon-Shiong summarizes the May 2021 phase 1 publication Safety, Tolerability, and Lo...

Advances in Treatment Options for BCG Unresponsive CIS and Papillary Non-Muscle Invasive Bladder Cancer - QUILT 3.032 - Sam Chang

Sam Chang joins Ashish Kamat to discuss the results of the QUILT study, which he presented at the GU ASCO 2022 annual meeting. QUILT 3.032 is an open-label, multicenter phase 3 study of intravesical bacillus calmette-guerin (BCG) plus N-803 in patients with BCG-unresponsive high-grade non-muscle-invasive bladder cancer (NMIBC) (NCT03022825) with CIS and papillary disease. Given the observed strong...